ScinoPharm Taiwan Ltd (1789) - Net Assets
Based on the latest financial reports, ScinoPharm Taiwan Ltd (1789) has net assets worth NT$10.52 Billion TWD (≈ $331.59 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$11.86 Billion ≈ $373.58 Million USD) and total liabilities (NT$1.33 Billion ≈ $42.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ScinoPharm Taiwan Ltd (1789) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$10.52 Billion |
| % of Total Assets | 88.76% |
| Annual Growth Rate | 8.23% |
| 5-Year Change | 0.13% |
| 10-Year Change | 2.9% |
| Growth Volatility | 14.99 |
ScinoPharm Taiwan Ltd - Net Assets Trend (2007–2025)
This chart illustrates how ScinoPharm Taiwan Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 1789 total asset value for the complete picture of this company's asset base.
Annual Net Assets for ScinoPharm Taiwan Ltd (2007–2025)
The table below shows the annual net assets of ScinoPharm Taiwan Ltd from 2007 to 2025. For live valuation and market cap data, see market value of ScinoPharm Taiwan Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$10.52 Billion ≈ $331.59 Million |
-0.01% |
| 2024-12-31 | NT$10.53 Billion ≈ $331.62 Million |
+1.56% |
| 2023-12-31 | NT$10.36 Billion ≈ $326.54 Million |
-0.82% |
| 2022-12-31 | NT$10.45 Billion ≈ $329.23 Million |
-0.58% |
| 2021-12-31 | NT$10.51 Billion ≈ $331.16 Million |
-0.17% |
| 2020-12-31 | NT$10.53 Billion ≈ $331.73 Million |
+2.63% |
| 2019-12-31 | NT$10.26 Billion ≈ $323.24 Million |
-2.65% |
| 2018-12-31 | NT$10.54 Billion ≈ $332.04 Million |
+1.17% |
| 2017-12-31 | NT$10.42 Billion ≈ $328.20 Million |
+1.85% |
| 2016-12-31 | NT$10.23 Billion ≈ $322.23 Million |
+3.76% |
| 2015-12-31 | NT$9.86 Billion ≈ $310.55 Million |
+5.08% |
| 2014-12-31 | NT$9.38 Billion ≈ $295.53 Million |
-2.73% |
| 2013-12-31 | NT$9.64 Billion ≈ $303.82 Million |
+6.31% |
| 2012-12-31 | NT$9.07 Billion ≈ $285.78 Million |
+5.97% |
| 2011-12-31 | NT$8.56 Billion ≈ $269.67 Million |
+28.19% |
| 2010-12-31 | NT$6.68 Billion ≈ $210.37 Million |
+49.31% |
| 2009-12-31 | NT$4.47 Billion ≈ $140.89 Million |
+29.99% |
| 2008-12-31 | NT$3.44 Billion ≈ $108.39 Million |
+35.79% |
| 2007-12-31 | NT$2.53 Billion ≈ $79.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ScinoPharm Taiwan Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 333998400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$366.45 Million | 3.48% |
| Common Stock | NT$7.91 Billion | 75.13% |
| Other Comprehensive Income | NT$976.28 Million | 9.28% |
| Other Components | NT$1.27 Billion | 12.11% |
| Total Equity | NT$10.52 Billion | 100.00% |
ScinoPharm Taiwan Ltd Competitors by Market Cap
The table below lists competitors of ScinoPharm Taiwan Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Tianyi Medical Appliance Co. Ltd.
SHE:301097
|
$505.73 Million |
|
Shanxi C&Y Pharmaceutical Group Co Ltd
SHE:300254
|
$505.94 Million |
|
Fenix Outdoor International AG
ST:FOI-B
|
$506.15 Million |
|
Dada Nexus Ltd
NASDAQ:DADA
|
$506.16 Million |
|
Yulon Nissan Motor Co Ltd
TW:2227
|
$505.66 Million |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
$505.54 Million |
|
NH SPAC 8
KQ:225570
|
$505.45 Million |
|
Addiko Bank AG
VI:ADKO
|
$505.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ScinoPharm Taiwan Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,525,804,000 to 10,524,737,000, a change of -1,067,000 (-0.0%).
- Net income of 136,951,000 contributed positively to equity growth.
- Dividend payments of 276,759,000 reduced retained earnings.
- Other comprehensive income increased equity by 103,913,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$136.95 Million | +1.3% |
| Dividends Paid | NT$276.76 Million | -2.63% |
| Other Comprehensive Income | NT$103.91 Million | +0.99% |
| Other Changes | NT$34.83 Million | +0.33% |
| Total Change | NT$- | -0.01% |
Book Value vs Market Value Analysis
This analysis compares ScinoPharm Taiwan Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.54x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | NT$3.67 | NT$20.30 | x |
| 2008-12-31 | NT$4.98 | NT$20.30 | x |
| 2009-12-31 | NT$6.47 | NT$20.30 | x |
| 2010-12-31 | NT$9.25 | NT$20.30 | x |
| 2011-12-31 | NT$11.10 | NT$20.30 | x |
| 2012-12-31 | NT$11.47 | NT$20.30 | x |
| 2013-12-31 | NT$12.19 | NT$20.30 | x |
| 2014-12-31 | NT$11.86 | NT$20.30 | x |
| 2015-12-31 | NT$12.44 | NT$20.30 | x |
| 2016-12-31 | NT$12.89 | NT$20.30 | x |
| 2017-12-31 | NT$13.14 | NT$20.30 | x |
| 2018-12-31 | NT$13.29 | NT$20.30 | x |
| 2019-12-31 | NT$12.95 | NT$20.30 | x |
| 2020-12-31 | NT$13.29 | NT$20.30 | x |
| 2021-12-31 | NT$13.27 | NT$20.30 | x |
| 2022-12-31 | NT$13.18 | NT$20.30 | x |
| 2023-12-31 | NT$13.08 | NT$20.30 | x |
| 2024-12-31 | NT$13.28 | NT$20.30 | x |
| 2025-12-31 | NT$13.06 | NT$20.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ScinoPharm Taiwan Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.33%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.13x
- Recent ROE (1.30%) is below the historical average (8.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 24.21% | 24.59% | 0.44x | 2.22x | NT$359.92 Million |
| 2008 | 25.36% | 27.67% | 0.55x | 1.68x | NT$528.25 Million |
| 2009 | 23.28% | 27.30% | 0.65x | 1.30x | NT$593.83 Million |
| 2010 | 15.58% | 26.73% | 0.53x | 1.09x | NT$372.28 Million |
| 2011 | 11.20% | 24.27% | 0.42x | 1.11x | NT$102.82 Million |
| 2012 | 12.91% | 25.61% | 0.44x | 1.14x | NT$263.96 Million |
| 2013 | 13.21% | 25.03% | 0.44x | 1.19x | NT$309.08 Million |
| 2014 | 5.16% | 11.81% | 0.36x | 1.21x | NT$-453.88 Million |
| 2015 | 6.44% | 16.05% | 0.32x | 1.24x | NT$-350.73 Million |
| 2016 | 6.44% | 16.34% | 0.32x | 1.25x | NT$-364.09 Million |
| 2017 | 4.05% | 12.01% | 0.28x | 1.22x | NT$-619.36 Million |
| 2018 | 4.20% | 12.57% | 0.28x | 1.19x | NT$-610.93 Million |
| 2019 | 2.11% | 7.49% | 0.25x | 1.14x | NT$-809.34 Million |
| 2020 | 2.68% | 9.15% | 0.26x | 1.13x | NT$-770.87 Million |
| 2021 | 2.32% | 8.81% | 0.24x | 1.11x | NT$-807.63 Million |
| 2022 | 3.38% | 10.82% | 0.27x | 1.14x | NT$-691.79 Million |
| 2023 | 2.77% | 9.01% | 0.27x | 1.13x | NT$-749.39 Million |
| 2024 | 3.22% | 9.96% | 0.29x | 1.13x | NT$-713.23 Million |
| 2025 | 1.30% | 4.33% | 0.27x | 1.13x | NT$-915.52 Million |
Industry Comparison
This section compares ScinoPharm Taiwan Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,042,622,889
- Average return on equity (ROE) among peers: 5.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ScinoPharm Taiwan Ltd (1789) | NT$10.52 Billion | 24.21% | 0.13x | $505.73 Million |
| Grape King Bio Ltd (1707) | $1.77 Billion | 10.20% | 0.42x | $525.05 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.98 Billion | 9.81% | 0.25x | $343.42 Million |
| Maywufa Co Ltd (1731) | $1.65 Billion | 2.55% | 0.49x | $90.66 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $7.70 Billion | 0.10% | 1.03x | $1.83 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $788.18 Million | -2.86% | 0.45x | $49.64 Million |
| LIWANLI Innovation Co Ltd (3054) | $661.02 Million | 0.00% | 0.12x | $167.70 Million |
| YungShin Global Holding Corp (3705) | $5.06 Billion | 9.31% | 0.15x | $466.59 Million |
| TTY Biopharm Co Ltd (4105) | $7.51 Billion | 19.30% | 0.45x | $581.27 Million |
| Phytohealth Corp (4108) | $2.27 Billion | -2.08% | 0.04x | $76.66 Million |
About ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract ma… Read more